Facebook'ta Paylaş
Tweetle
Google Plus'ta Paylaş

doxycycline good for trichomoniasis

  • Derecelendirme: 0/5 - 0 oy
  • Beğen
0
Konuyu Beğen
0
#1
source Fletcher and Griffin, 1986. <a href=https://buydoxycyclineon.com/>doxycycline for dogs side effects</a> NSAIDs requires close monitoring for signs of systemic toxicity; not studied in patients with renal impairment Thrombocytopenia, neutropenia, and anemia monitor blood counts and omit and or reduce dose for hematologic toxicities; mucositis monitor at least weekly; if grade 2 mucositis is observed, omit and or reduce dose; dermatologic reactions reactions, including fatal reactions, have occurred and may be progressive and increase in severity with further treatment; monitor closely, and omit and or reduce dose or discontinue drug; tumor lysis syndrome anticipate, monitor, and treat promptly; hepatic toxicity monitor for toxicity; for liver function test abnormalities grade 3 or greater, omit until recovery and then reduce dose or discontinue therapy as required; risk of increased toxicity with renal impairment patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity; monitor patients for renal function and systemic toxicity and adjust dosing accordingly; avoid use in patients with end- stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk Relapsed, refractory peripheral T- cell lymphoma Pralsetinib Gavreto RET kinase inhibitor Avoid strong CYP3A inhibitors, combined P- gp and strong CYP3A inhibitors, and strong CYP3A inducers Interstitial lung disease, hypertension, hepatotoxicity, hemorrhagic events, impaired wound healing, constipation, musculoskeletal pain, myelosuppression Metastatic RET fusion- positive NSCLC Prednisone Deltasone, others Corticosteroid Good oral bioavailability; extensively metabolized in liver, primarily to active form of drug, prednisolone; half- life of 4 hr; liver disease may decrease conversion to the active form, requiring use of prednisolone instead of prednisone; routes of excretion are not well delineated Toxicity is mostly in the form of constitutional symptoms, including mood changes depressive, anxious, or euphoric, insomnia, indigestion, enhanced appetite, weight gain, acne, and cushingoid features; other adverse effects may be more serious but are less common; hyperglycemia and increased stomach acid predisposing to ulceration occur acutely, and osteopenia, cataracts, skin atrophy, and adrenal insufficiency occur with prolonged use Approved for a wide variety of malignant and nonmalignant conditions; used in oncology for lymphoid malignancies, for palliative care, and for management of adverse effects toxicities Procarbazine Matulane, N- methylhydrazine Alkylating agent; cell cycle independent Well absorbed by the oral route, reaching peak plasma levels in 1 hr, with good distribution to the cerebrospinal fluid; procarbazine is metabolized by the liver and has an elimination half- life of about 1 hr; largely excreted in the urine Myelosuppression is expected and dose limiting, but anemia is uncommon; nausea and vomiting are common and can be dose limiting as well; rash, hives, and photosensitivity sometimes occur; other adverse effects are uncommon and include anorexia, diarrhea, stomatitis, hypotension, tachycardia, syncope, flulike symptoms, interstitial pneumonitis, CNS excitation including seizures, and secondary malignancies Approved for Hodgkin disease and may also be useful in non- Hodgkin lymphoma, multiple myeloma, brain tumors, melanoma, and lung cancer Radium 223 Xofigo Alpha particle emitter Requires appropriate setting for administration with necessary radiation safety Bone marrow suppression; nausea, diarrhea Castration- resistant prostate cancer with symptomatic bone metastases and no visceral metastases Ramucirumab Cyramza Monoclonal antibody targeting the vascular growth factor receptor 2, inhibiting endothelial cell proliferation and angiogenesis Half- life 14 days Infusion reaction; hypertension; proteinuria; arterial thrombosis; GI perforation; bleeding Metastatic colorectal cancer in combination with FOLFIRI following progression on FOLFOX and bevacizumab; gastric cancer as a single agent or in combination with paclitaxel following progression on a fluoropyrimidine or platinum- containing regimen; NSCLC in combination with paclitaxel for advanced disease after platinum- based treatment Rasburicase Elitek Recombinant urate oxidase No drug interaction studies have been conducted in humans; of the total number of adults treated with Elitek n 434 in clinical studies, 30 were 65 yr and older and 8 were 75 yr and older; no overall differences in pharmacokinetics, safety, and effectiveness were observed between the elderly and younger patients Anaphylaxis, hemolysis, methemoglobinemia are boxed warnings Management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies Regorafenib Stivarga Inhibits many membrane and intracellular kinases including RET, VEGFR, KIT, PDGFR, FGF, TIE2, DDR2, TrkA, Eph2A, RAF- 1, BRAF, CSF1R Take with food; decreased exposure with strong inducers of CYP3A Hepatotoxicity, fatigue, decreased appetite, hand- foot skin reaction Previously treated metastatic colorectal cancer; gastrointestinal stromal tumor; hepatocellular carcinoma Ribociclib Kisqali Small molecule inhibitor of cyclin- dependent kinases 4 and 6; produces G1 cell cycle arrest; combined with aromatase inhibitors leads to enhanced tumor cell growth control Metabolized in the liver by CYP3A4 Bone marrow suppression; hepatotoxicity with abnormal liver function; QT prolongation; peripheral edema; fatigue; alopecia; skin rash; hypokalemia; nausea and diarrhea; increased serum creatinine Advanced breast cancer for patients with HR- positive, HER2- negative disease in combination with an aromatase inhibitor as initial endocrine therapy Ripretinib Qinlock Type II tyrosine kinase switch control inhibitor Avoid strong CYP3A inducers, monitor carefully with strong CYP3A inhibitors Palmar- plantar erythrodysesthesia syndrome, new primary cutaneous malignancies, hypertension, cardiac dysfunction, impaired wound healing, alopecia, nausea, abdominal pain, constipation, myalgia, diarrhea Advanced gastrointestinal stromal tumor despite 3 or more prior kinase inhibitors, including imatinib Rituximab Rituxan Monoclonal antibody directed against the B- cell surface antigen CD20 When given IV, it is taken up by B lymphocytes and then degraded throughout the body by proteolysis, with a wide- ranging serum half- life of 11- 105 hr mean 60 hr with the first dose; there is no appreciable excretion of this polypeptide Fever, chills, and malaise are common during administration, even with premedication with acetaminophen and diphenhydramine; other infusion- related symptoms include nausea, vomiting, flushing, urticaria, angioedema, hypotension, dyspnea, bronchospasm, fatigue, headache, rhinitis, and pain at disease sites; these symptoms are generally self- limited, improve with slowing of the infusion, and resolve after infusion; short- lived myelosuppression, abdominal pain, and myalgia are uncommon; arrhythmias and angina pectoris are rare Relapsed or refractory low- grade or follicular, CD20- positive, B- cell lymphomas Romidepsin Istodax HDAC inhibitor Carefully monitor PT and INR in patients concurrently taking coumadin derivatives; strong CYP3A4 inhibitors may increase pralatrexate concentrations and should be avoided; potent CYP3A4 inducers may decrease concentrations of pralatrexate and should be avoided The most common adverse reactions were neutropenia, lymphopenia, thrombocytopenia, infections, nausea, fatigue, vomiting, anorexia, anemia, and ECG T- wave changes Treatment of peripheral or CTCL in patients who have received at least one prior systemic therapy Rucaparib Rubraca Inhibits poly ADP- ribose polymerase enzyme isoforms essential for DNA repair; increased cell killing in tumors deficient in BRCA1 2 repair pathway Metabolized by CYP2D6 in the liver Fatigue and dizziness; skin rash; increased cholesterol; nausea, constipation; diarrhea; blood count suppression; increased liver function tests; increased serum creatinine; weakness; dyspnea; fever Advanced ovarian cancer in presence of BRCA mutations germline or somatic detected by an approved diagnostic test as third- line therapy Ruxolitinib Jakafi JAK kinase signaling inhibitor With or without food; reduce dose 50 with strong CYP3A inhibitors, moderate renal or hepatic impairment Thrombocytopenia, anemia, bruising, dizziness, headache Intermediate or high- risk myelofibrosis Sacituzumab govitecan- hziy Trodelvy Trop- 2- directed antibody and topoisomerase inhibitor conjugate Individuals who are homozygous for the uridine diphosphate- glucuronosyl transferase 1A1 UGT1A1 28 allele are at increased risk for neutropenia Neutropenia, severe diarrhea, hypersensitivity reactions, nausea, vomiting, anemia, alopecia, constipation, rash, abdominal pain Metastatic triple- negative breast cancer despite at least two prior therapies Sargramostim Leukine, Leukomax, GM- CSF Cytokine; exhibits pleiotropic stimulatory effects on bone marrow progenitor cells Similar bioavailability when given IV or SC; degraded throughout the body, predominantly in the liver and kidneys, with an elimination half- life of 2 hr; no appreciable excretion of this peptide occurs Constitutional symptoms, which tend to decrease over time, predominate at standard doses; higher doses may cause capillary leak syndrome; adverse effects include flushing, hypotension or hypertension, dyspnea, fever, nausea, vomiting, fatigue, myalgias, bone pain, headache, and skin rash; thrombocytopenia may also occur; fluid retention and edema rarely occur at standard doses; progression of myelodysplastic syndrome has been documented in patients on GM- CSF FDA approved for the treatment of myelosuppression after ABMT; may be useful to minimize myelosuppression after standard- dose chemotherapy or to shorten the course of neutropenic fever Selinexor Xpovio Nuclear export inhibitor 95 protein bound; metabolized by liver Thrombocytopenia, neutropenia, gastrointestinal toxicity, hyponatremia, serious infection, neurological toxicity With dexamethasone for relapsed or refractory multiple myeloma despite at least four prior therapies; or refractory diffuse large B- cell lymphoma, including disease arising from follicular lymphoma, after at least 2 lines of systemic therapy Selpercatinib Retevmo Proto- oncogene receptor tyrosine kinase RET kinase inhibitor Avoid proton pump inhibitors, strong and moderate CYP3A inhibitors, strong and moderate CYP3A inducers, and CYP2C8 and CYP3A substrates Hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, impaired wound healing, hyperglycemia, neutropenia, increased total cholesterol Metastatic RET fusion- positive NSCLC Sipuleucel- T Provenge Autologous vaccine No studies performed Chills, fatigue, fever, back pain, nausea, joint ache, and headache Metastatic castrate- resistant hormone refractory prostate cancer Sonidegib Odomzo Hedgehog pathway inhibitor that binds and inhibits Smoothened, a transmembrane protein essential for Hedgehog signaling Metabolized in the liver by CYP3A Fatigue; alopecia; hyperglycemia; abnormal liver function tests; anemia; increased CPK, muscle pain; increased serum creatinine Locally advanced basal cell carcinoma recurrent after surgery or radiation therapy Sorafenib Nexavar Oral multikinase inhibitor that interacts with multiple intracellular CRAD, BRAF and cell surface kinases KIT, FLT- 3, VEGFR- 2, VEGFR- 2, and PDGFR; may inhibit angiogenesis Metabolized in the liver; drug and metabolites are excreted primarily in the feces Skin toxicity with rash and hand- foot syndrome; nausea, vomiting, anorexia, diarrhea; asthenia, pain, arthralgias; hypertension; bleeding events, especially in anticoagulated patients; cardiac ischemia; myelosuppression Advanced renal cell carcinoma Streptozocin Zanosar Alkylating agent; cell cycle independent Metabolized primarily in the liver and has an elimination half- life of GI adverse effects nausea, vomiting, and cramping or nephrotoxicity glomerular and tubular damage are common and potentially dose limiting; myelosuppression is less often dose limiting; elevated liver function tests can occur occasionally but are rarely clinically significant; fever, delirium, and depression occur rarely; streptozocin is an irritant if extravasated into perivenous soft tissue Approved for metastatic islet cell carcinoma and may also be useful for advanced carcinoid tumor, pancreatic carcinoma, and Hodgkin disease Sunitinib maleate Sutent Inhibits PDGFR- A and PDGFR- B, VEGFR1- 3, stem cell factor receptor, FLT- 3, CSF- 1R, and the neurotrophic factor receptor; this inhibition inhibits tumor growth and metastases Metabolized in the liver with elimination primarily in the feces; half- life is 40- 60 hr for the drug and 80- 110 hr for its primary metabolite Cardiotoxicity usually reversible; bleeding events, epistaxis most common; hypertension; myelosuppression; nausea, vomiting; rash; liver function test alterations Advanced renal cell carcinoma; second- line therapy for GIST cell tumors; also approved for pancreatic neuroendocrine tumors Tafasitamab- cxix Monjuvi CD19- directed cytolytic antibody Administer with lenalidomide for up to 12 cycles and then continue as monotherapy Infusion- related reactions, myelosuppression, infections, diarrhea, cough, peripheral edema In combination with lenalidomide for relapsed or refractory diffuse large B- cell lymphoma not eligible for autologous HSCT Tagraxofusp- erzs Elzonris CD123- directed cytotoxin Premedicate with H1- histamine antagonist, acetaminophen, corticosteroid, and H2- histamine antagonist prior to each infusion Hypersensitivity, hepatotoxicity, capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, weight increase Blastic plasmacytoid dendritic cell neoplasm Talazoparib Talzenna PARP inhibitor Reduce dose if moderate renal impairment creatinine clearance 30- 59 mL min Myelodysplastic syndrome, AML, myelosuppression, nausea, headache, vomiting, alopecia, diarrhea Germline BRCA- mutated HER2- negative locally advanced or metastatic breast cancer Talimogene Laherparepvec Imlygic; T- VEC Attenuated herpes simplex virus 1 oncolytic virus; virally derived GM- CSF activates antitumor immune response No dose adjustments for renal or hepatic dysfunction Fatigue; chills; nausea; pain at injection site; myalgias; flulike symptoms; fever Unresectable melanoma Tamoxifen Nolvadex Nonsteroidal antiestrogen; cytostatic effects on estrogen- dependent and nondependent malignant cells Tamoxifen has good oral bioavailability, is metabolized in the liver, and has an elimination half- life of about 7 days; neither tamoxifen nor its major metabolite is found in the bile or urine Tamoxifen is usually very well tolerated; constitutional symptoms are most prevalent and usually dose limiting; hot flashes, sweating, mood changes, weight gain or loss, and stomach upset are most common; nausea, vomiting, diarrhea, and constipation are less common; menstrual changes, including significant vaginal bleeding, are uncommon; venous thromboembolism, myelosuppression, and retinopathy are rare Approved for the treatment of breast cancer, generally in postmenopausal patients or those with ER tumors; the same dose has been approved for chemoprevention of breast cancer in high- risk individuals; higher doses are used for melanoma and pancreatic cancer Tazemetostat Tazverik Methyltransferase inhibitor Avoid strong and moderate CYP3A inhibitors and strong and moderate CYP3A inducers Fatigue, nausea, vomiting, constipation, upper respiratory tract infection, musculoskeletal pain, abdominal pain Metastatic or unresectable locally advanced epithelioid sarcoma, relapsed or refractory follicular lymphoma with an EZH2 mutation or no alternative treatment options Temozolomide Temodar Atypical alkylator semiselective DNA methylator drug sharing the same active metabolite as dacarbazine, MTIC but, unlike dacarbazine, is spontaneously converted to MTIC and also penetrates the blood- brain barrier effectively Temozolomide has good bioavailability, enhanced by an empty stomach; after absorption into the bloodstream, it is spontaneously converted to the active moiety MTIC; peak plasma concentrations occur in about 1 hr; the elimination half- life is about 1.


    doxycycline good for trichomoniasis
İlginizi çekebilir:
  • doxycycline for typhus
  • Konuyu Okuyanlar: 1 Ziyaretçi